GGrantIndex
← Search

CORE--LAB ANIMAL HEALTH

$299,797P30FY2009CANIH

Fox Chase Cancer Center, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567Paper 39602533Paper 39554190Paper 39546469Paper 39521739Paper 39514554Paper 39371220Paper 39345610Paper 39343653Paper 39223207Paper 39207123Paper 39189642Paper 39148468Paper 39137728Paper 39072643Paper 39060143Paper 39013784Paper 39003201Paper 38982062Paper 38976159Paper 38963567Paper 38914477Paper 38871720Paper 38865671Paper 38853421Paper 38835516Paper 38815457Paper 38811332Paper 38798370Paper 38766032Paper 38747616Paper 38678525Paper 38659828Paper 38639476Paper 38638131Paper 38600381Paper 38586274Paper 38586042Paper 38559274Paper 38547779Paper 38539515Paper 38464238Paper 38452871Paper 38432028Paper 38421650Paper 38377387Trial NCT04290585Trial NCT03177057Trial NCT02594826Trial NCT02132884Trial NCT02132858Trial NCT02132845Trial NCT02110953Trial NCT02092714Trial NCT02050009Trial NCT01982591Trial NCT01962948Trial NCT01934179Trial NCT01840150Trial NCT01462630Trial NCT01316757Trial NCT01212822Trial NCT00750009Trial NCT00509626Trial NCT00458588Trial NCT00436397Trial NCT00433524Trial NCT00084591Trial NCT00084539Trial NCT00084526Trial NCT00084513Trial NCT00066677Trial NCT00062322Trial NCT00062309Trial NCT00043108Trial NCT00039520Trial NCT00039507Trial NCT00022308Trial NCT00021398Trial NCT00021372Trial NCT00021346Trial NCT00021333Trial NCT00021320Trial NCT00005037Trial NCT00003264Trial NCT00003263Trial NCT00003109Patent 9533040Patent 9182383Patent 9101603Patent 8980258Patent 8685658Patent 8609437Patent 8580263Patent 8329873Patent 7332585Patent 7332580Patent 7129057Patent 6946275Patent 6617427

Abstract

The Laboratory Animal Health Facility (LAHF) supports an ever-increasing demand for the use of animals in the Fox Chase Cancer Center's (FCCC) Laboratory Animal Facility (LAF). In 2003, the LAHF supported 46 investigators in all 11 research Programs from all three Divisions at the Center. The vast majority (96%) of use was for peer-reviewed, funded research. The increase in mouse usage during the past five years was 116%, and the use of rodents is anticipated to expand approximately 100% in the next five years. Even as importation of mice from collaborators has increased by over 50% in the past five years, the Facility has maintained and improved the health of the colony. All new strains imported from other Facilities are held in quarantine and monitored for murine disease by serology and polymerase chain reaction (PCR) techniques;most have to be rederived by germ-free cesarean or embryo transfer and raised on disease-free foster mothers in microisolator units before permitted into the main research Facility. Over 81 such cesarean rederivations were done in 2003. The health of animals and their freedom from murine pathogens is constantly monitored by sentinel animals in each animal room, and the entire research Facility has remained viral antibody-free since 1998, Severe immune-deficient mice are bred and successfully live up to two years in the FCCC research colony. Pneumocystis, Pasteurella and Helicobacter have already been eliminated from all breeding and immunodeficient rodent areas, and continued systematic rederivation combined with increased microisolator housing is expected to completely eliminate these agents from all FCCC colonies within two years. In 2003, the LAHF performed 11,967 tests (5,600 microbiological cultures, 3,179 ELISA assays, 2,088 (PCR) assays, and 1,100 necropsies and the number of service hours of direct support to research investigators has increased 210% (1,912 in 2003). Technical support includes animal surgery, antibody production in rabbits, mice and rats, collecting samples from animals, tumor line maintenance, necropsies, tumor and cell culture screening, and microbiological/serological testing. The need for technical services has increased almost four-fold from 1998 (616 service hours) to 2003 (1,912 service hours). This increase is expected to continue parallel to the increase in animal numbers, and an increase of one FTE is projected.

View original record on NIH RePORTER →